Seeking Alpha

ISTA Pharmaceuticals (ISTA) falls 27.6% after reporting Q2 revenue and adjusted EPS of $37.1M...

ISTA Pharmaceuticals (ISTA) falls 27.6% after reporting Q2 revenue and adjusted EPS of $37.1M (+6% Y/Y) and -$0.11, below a consensus of  $41.9M and $0.05. Perhaps more importantly, ISTA is also reporting that a a Phase 3 study for its REMURA drug for treating dry eye disease showed that the drug "was not statistically significantly better" than a placebo.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector